A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.

By X. Pi-Sunyer, A. Astrup, K. Fujioka, F. Greenway, A. Halpern, M. Krempf, D. Lau, C. L. le Roux, R. V. Violante Ortiz, C. Jensen and 1 more. New England Journal of Medicine, 2015

2,142 citations recorded by the source corpus.

Subfields: Endocrinology, Diabetes and Metabolism, Pharmacology, Surgery

View Paper: https://www.semanticscholar.org/paper/01f6c765d4d399ef64124f5c0b619ed67ff94ebc

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Endocrinology, Diabetes and Metabolism

1. M. Blüher
2. T. Wadden

In Pharmacology

1. M. Blüher

In Surgery

1. M. Blüher
2. T. Wadden

Citations in the corpus

• Anti-obesity drug discovery: advances and challenges (2021, background): “Data in panel a refer to liraglutide 3 mg (rEF.(176)), orlistat(289), naltrexone/ bupropion(292), phentermine/topiramate(291), semaglutide 1 mg (rEF.”
• CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM--2016 EXECUTIVE SUMMARY. (2016, background): “Whether achieved through lifestyle therapy, pharmacotherapy, surgery, or some combination thereof, weight loss reduces insulin resistance and can effectively prevent progression to diabetes as well as improve plasma lipid profile and BP (44,48,49,51,53,60,63).”
• Once-Weekly Semaglutide in Adults with Overweight or Obesity. (2021, background): “0 mg.(35) No new safety concerns arose.”